NDAINTRAVENOUSSOLUTION
Approved
Jul 2022
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
15
Data completeness
3/8 — Basic
PEMETREXED DISODIUM (pemetrexed disodium) by Accord Biopharma is folate-dependent metabolic processes essential for cell replication. First approved in 2022.
Drug data last refreshed 58m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Pemetrexed disodium is a folate-dependent antimetabolite chemotherapy agent that inhibits multiple enzymes (thymidylate synthase, dihydrofolate reductase, and GARFT) essential for DNA synthesis and cell replication. It is administered intravenously as a solution and is approved for oncology indications. The drug works by disrupting nucleotide biosynthesis, particularly targeting rapidly dividing cancer cells.
Peak
The product is at peak lifecycle stage with moderate competitive pressure (30%), suggesting stable commercial activity and established team structures focused on market maintenance.
Mechanism of Action
folate-dependent metabolic processes essential for cell replication. In vitro studies show that pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase (GARFT), which are folate-dependent enzymes involved in the de novo biosynthesis…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (15)
Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer
Started Jan 2014
13 enrolled
Recurrent Non-small Cell Lung CancerSquamous Cell Lung CancerStage IV Non-small Cell Lung Cancer
Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy
Started Apr 2010
72 enrolled
Malignant Mesothelioma
Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer
Started Feb 2010
313 enrolled
Lung Cancer
Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Started Sep 2007
110 enrolled
Lung Cancer
Gemcitabine and Pemetrexed Disodium in Treating Patients With Advanced Mycosis Fungoides or Sézary Syndrome
Started Aug 2006
14 enrolled
Lymphoma
Worked on PEMETREXED DISODIUM at Accord Biopharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.